Skip to content

Trial Summary

DREAM3R

Acronym:

DREAM3R

ACTRN/NCT /ethics:

NCT04334759

Scientific title:

DuRvalumab with chEmotherapy vs chemotherapy alone as first line treAtment in advanced, pleural Mesothelioma – a phase 3 Randomised trial

Sponsor / Cooperative group:

PrECOG, LLC.

Trial & Patient Characteristics

Cancer TypeLung & mesothelioma
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2020-09-01
Anticipated End Date2025-05-01

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Emailpamela.cooper@sa.gov.au
Phone08 8222 6140
Principal InvestigatorDr Rachel Roberts-Thomson
Recruitment StatusNot Yet Recruiting